Abstract
Patients with normal immune systems may be unable to mount effective defences against solid tumours because of (1) the generation of suppressor T cells in the low zone tolerance response elicited by the low concentrations of antigen furnished by slow growing solid tumours; (2) the ineffectiveness of the cytolytic T-cell response when the tumour cell membrane lacks the major histocompatibility gene products required for linkage to tumour antigens; and (3) the hindrance of antibody-dependent cellular cytotoxicity by antitumour antibodies when the precise requirements for the reaction cannot be fulfilled in the sites occupied by solid tumours. Recent immunological advances suggest that it should be possible to isolate antigens from cancer cells, produce antibodies against these antigens, bind the antibodies to the patient's macrophages and K lymphocytes, and reinject the bound cells into the patient to stimulate lymphokine synthesis and antibody-dependent cellular cytoxicity.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
